Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Samsung Bioepis Co., Ltd. clinical trials
Part of Samsung Epis Holdings Co., Ltd., which holds 100% as of 2025-12-31. Source
The registry lists 33 studies whose lead sponsor is Samsung Bioepis Co., Ltd.. 2 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 15, 2026.
Keep track of what changes. Save the Samsung Bioepis Co., Ltd. studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Samsung Bioepis Co., Ltd..
- Samsung Bioepis Co., Ltd.33 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 33 of 33.
- A Study to Compare the Pharmacokinetics, Safety, Tolerability, and Immunogenicity of SB35 (Proposed Ixekizumab Biosimilar) to Taltz in Healthy ParticipantsRecruitingNCT07789964Phase 1
- A Trial to Investigate the Safety of E303 in Participants With Advanced Refractory Solid TumorsRecruitingNCT07524348Phase 1
- A Trial to Evaluate the Safety and Usability of the SB15 PFS in Trial Participants With AMD, Macular Oedema Secondary to RVO, or Diabetic Macular OedemaCompletedNCT07844343Phase 2
- A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung CancerActive, not recruitingNCT06348199Phase 3
- A Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Pembrolizumab (SB27, EU Sourced Keytruda, and US Sourced Keytruda) in Subjects With Stage II-IIIA NSCLC Following Complete Resection and Adjuvant Platinum-based ChemotherapyActive, not recruitingNCT06268613Phase 1
- A Study to Evaluate the Usability of the SB11 PFS in Trial Participants With Wet AMD, Macular Oedema Secondary to RVO, or mCNVCompletedNCT07550504Phase 2
- A Study to Compare SB17 (Proposed Ustekinumab Biosimilar) to Stelara® in Subject With Moderate to Severe Plaque PsoriasisCompletedNCT04967508Phase 3
- A Study to Compare SB16 (Proposed Denosumab Biosimilar) to Prolia® in Postmenopausal Women With OsteoporosisCompletedNCT04664959Phase 3
- A Study to Evaluate the Usability of the SB11 PFS in Subjects With Wet AMD or Macular Oedema Secondary to RVOCompletedNCT06176963Phase 2
- A Study Comparing SB8 and Avastin® in Patients With Advanced Non-squamous Non-small Cell Lung CancerCompletedNCT02754882Phase 3
- A Study to Compare SB12 (Proposed Eculizumab Biosimilar) to Soliris in Subjects With Paroxysmal Nocturnal HaemoglobinuriaCompletedNCT04058158Phase 3
- A Study to Compare SB15 (Proposed Aflibercept Biosimilar) to Eylea in Subjects With Neovascular Age-related Macular Degeneration (AMD)CompletedNCT04450329Phase 3
- A Long-term Follow-up Study for Cardiac Safety in the Patients With HER2 (+) Breast Cancer Who Have Completed the SB3-G31-BCTerminatedNCT02771795
- Pharmacokinetics, Efficacy, Safety, and Immunogenicity of SB5 Versus Humira in Subjects With Moderate to Severe Chronic Plaque PsoriasisCompletedNCT05510063Phase 4
- Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity Study of SB16 in Healthy Male SubjectsCompletedNCT04621318Phase 1
- A Study to Compare SB17 (Proposed Ustekinumab Biosimilar) to European Union (EU) Sourced Stelara and United States of America (US) Sourced Stelara in Healthy SubjectsCompletedNCT04772274Phase 1
- Pharmacokinetics, Safety, Tolerability, and Immunogenicity of Two Formulations of SB5 in Healthy Male SubjectsCompletedNCT04514796Phase 1
- A Study to Compare SB11 (Proposed Ranibizumab Biosimilar) to Lucentis in Subjects With Neovascular Age-related Macular Degeneration (AMD)CompletedNCT03150589Phase 3
- A Phase I Study of SB26 in Healthy VolunteersCompletedNCT03630627Phase 1
- Pharmacokinetic, Safety, Tolerability, Immunogenicity, and Pharmacodynamic Study of SB12 in Healthy SubjectsCompletedNCT03722329Phase 1
- Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB4 in Healthy Male SubjectsCompletedNCT01865552Phase 1
- Pharmacokinetic, Safety, Tolerability, and Immunogenicity Study of SB8 in Healthy Male SubjectsCompletedNCT02453672Phase 1
- An Multicentre Clinical Study to Evaluate the Usability and Safety of the Pre-filled Pen and Pre-filled Syringe of SB5 in Subjects With Rheumatoid ArthritisCompletedNCT02565810Phase 2
- Pharmacokinetics, Safety, and Tolerability Study of the Pen and PFS of SB5 in Healthy SubjectsCompletedNCT02326233Phase 1
- Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB2 in Healthy SubjectsCompletedNCT01922336Phase 1
- Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB5 in Healthy SubjectsCompletedNCT02144714Phase 1
- A Study to Compare the Effect of SB3 and Herceptin® in Women With HER2 Positive Breast CancerCompletedNCT02149524Phase 3
- An Multicentre Clinical Study to Evaluate the Usability and Safety of the Autoinjector and Pre-filled Syringe of SB4 in Subjects With Rheumatoid ArthritisCompletedNCT03193957Phase 2
- Pharmacokinetics, Safety, and Tolerability Study of the Autoinjector and Pre-filled Syringe of SB4 in Healthy Male SubjectsCompletedNCT03193203Phase 1
- Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB3 in Healthy Male SubjectsCompletedNCT02075073Phase 1
- A Study Comparing SB2 to Remicade® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate TherapyCompletedNCT01936181Phase 3
- A Study Comparing SB5 to Humira® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate TherapyCompletedNCT02167139Phase 3
- A Study Comparing SB4 to Enbrel® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate TherapyCompletedNCT01895309Phase 3